In this roundtable discussion featuring a panel of experts, Dr Gregory Mattingly, Dr Richard Price, and Dr Birgit Amann focus on the evolving future of the ADHD landscape and address current unmet needs in ADHD treatment for both adult and...
In this roundtable discussion featuring a panel of experts, Dr Gregory Mattingly, Dr Richard Price, and Dr Birgit Amann focus on the evolving future of the ADHD landscape and address current unmet needs in ADHD treatment for both adult and...
In this roundtable discussion featuring a panel of experts, Dr Gregory Mattingly, Dr Richard Price, and Dr Birgit Amann delve into the evolving landscape of ADHD treatment. The panelists discuss current treatment options, including...
In this roundtable discussion featuring a panel of experts, Dr Gregory Mattingly, Dr Richard Price, and Dr Birgit Amann delve into the evolving landscape of ADHD treatment. The panelists discuss current treatment options, including...
In this roundtable discussion featuring a panel of experts, Dr Gregory Mattingly, Dr Richard Price, and Dr Birgit Amann explore key findings from the real-world study comparing viloxazine ER with atomoxetine for ADHD treatment in adult and...
In this roundtable discussion featuring a panel of experts, Dr Gregory Mattingly, Dr Richard Price, and Dr Birgit Amann explore key findings from the real-world study comparing viloxazine ER with atomoxetine for ADHD treatment in adult and...
Manpreet Singh, MD, MS, discusses introducing stimulant therapy for ADHD management, differentiating pediatric ADHD from mood disorders, and gender or ethnic bias during diagnosis.
Manpreet Singh, MD, MS, discusses introducing stimulant therapy for ADHD management, differentiating pediatric ADHD from mood disorders, and gender or ethnic bias during diagnosis.
Manpreet K Singh, MD, MS, offers "clinical clues" to clinicians on how to distinguish ADHD from primary mood disorders or other conditions and also discusses comorbid conditions in pediatric ADHD.
Manpreet K Singh, MD, MS, offers "clinical clues" to clinicians on how to distinguish ADHD from primary mood disorders or other conditions and also discusses comorbid conditions in pediatric ADHD.
Manpreet K Singh, MD, MS, director, offers tips for clinicians to maintain manage expectations and the best possible care for patients with ADHD throughout the holiday season.
Manpreet K Singh, MD, MS, director, offers tips for clinicians to maintain manage expectations and the best possible care for patients with ADHD throughout the holiday season.
Andrew J. Cutler, MD, discusses the newer medications in development and recently approved to treat ADHD. It is “a very exciting time” as there a number of newer treatment options, allowing clinicians to personalize treatment for their...
Andrew J. Cutler, MD, discusses the newer medications in development and recently approved to treat ADHD. It is “a very exciting time” as there a number of newer treatment options, allowing clinicians to personalize treatment for their...
Psych Congress Steering Committee member Rakesh Jain, MD, MPH, discusses an article he cowrote on nonstimulant treatment options for pediatric attention-deficit/hyperactivity disorder (ADHD).
Psych Congress Steering Committee member Rakesh Jain, MD, MPH, discusses an article he cowrote on nonstimulant treatment options for pediatric attention-deficit/hyperactivity disorder (ADHD).
Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN
Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.